Home-administered tDCS for Treatment of Depression

Status Completed

Clinical Trial Summary

This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT. 32 tDCS sessions of 30 minutes each will be delivered over 10 weeks.

Clinical Trial Description

The Soterix Medical 1X1 mini-CT will be used to determine the safety and efficacy of home-based transcranial direct current stimulation (tDCS) in treating unipolar depression. Specifically efficacy will be determined by change in MADRS score from baseline to the 10 week follow-up. Feasibility and compliance will be determined by low drop out rate and percentage of scheduled sessions completed. Self-reported mood scores will be evaluated using the Quick Inventory of Depressive Symptomatology (QIDS-SR) and Quality of Life enjoyment and Satisfaction Questionnaire Form (Q-LES-Q-SF). All visits will be performed via telephone or video conference. Subjects will be taught to operate the tDCS system and complete a tolerability check. The treatment course will consist of an acute phase of 28 tDCS sessions conducted Monday - Friday over 6 weeks. This is followed by a taper of 4 tDCS sessions spaced 1 week apart. Patients who meet criteria for clinical response (>=50% improvement in MADRS) may continue with maintenance treatments of once a week for 2 months and once every 2 weeks for the remaining 3 months. Mood assessments will be conducted at baseline, 2 weeks, 4 weeks and 6 weeks in the acute treatment phase. In the taper phase, assessments wil be conducted at 1 month (end of taper), 3 and 6 months following completion of the acute phase. All assessments in the acute treatment phase and the taper phase will have a +/- 1 week collection window. ;

Study Design

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression
Unipolar Depression

Clinical Trial Details

NCT number	NCT04781127
Study type	Interventional
Source	Soterix Medical
Contact
Status	Completed
Phase	Phase 1
Start date	February 10, 2021
Completion date	August 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04124341` - PCS in Severe Treatment Resistant Depression	N/A
Recruiting	`NCT03887715` - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A
Completed	`NCT04727229` - Stellate Ganglion Block for Major Depressive Disorder.	Phase 4
Completed	`NCT04634669` - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)	Phase 2
Withdrawn	`NCT03175887` - Investigational TMS Treatment for Depression	N/A
Completed	`NCT03134066` - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting	`NCT01984710` - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S	N/A
Completed	`NCT01935115` - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	Phase 4
Terminated	`NCT01687478` - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression	Phase 3
Completed	`NCT00531726` - Berlin Deep Brain Stimulation Depression Study	N/A
Recruiting	`NCT04041479` - Biomarker-guided rTMS for Treatment Resistant Depression	Phase 3
Recruiting	`NCT05870540` - BPL-003 Efficacy and Safety in Treatment Resistant Depression	Phase 2
Recruiting	`NCT04959253` - Psilocybin in Depression Resistant to Standard Treatments	Phase 2
Completed	`NCT04856124` - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting	`NCT03272698` - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression	Phase 4
Active, not recruiting	`NCT04451135` - CET- REM (Correlating ECT Response to EEG Markers)	N/A
Completed	`NCT03288675` - Stepped Care aiTBS 2 Depression Study (Ghent)	N/A
Recruiting	`NCT06138691` - KET-RO Plus RO DBT for Treatment Resistant Depression	Phase 1
Terminated	`NCT02675556` - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression	Phase 1
Recruiting	`NCT03952962` - Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression	N/A